ArticleThe international journal of cardiovascular imaging2026
Left atrial cardiomyopathy: association with atrial fibrillation and stroke recurrence.
Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the association between functional and structural markers of left atrial (LA) dysfunction in patients with stroke of either (i) undetermined etiology or (ii) small or large-vessel stroke, and the recurrence of stroke or new-onset atrial fibrillation (AF). METHODS AND
resultsBetween 2019 and 2021 we consecutively included 91 patients with a recent stroke (< 30 days) without known or detected AF. All patients had cardiac magnetic resonance with late gadolinium enhancement to determine LA Emptying Fraction (LAEF), LA volumes, and LA fibrosis. Stroke adjudications were performed according to Trial of Org 10,172 in Acute Stroke Treatment classification as either undetermined etiology (n = 48) or stroke from large- or small-vessel disease (n = 43). The primary endpoint was a composite of stroke recurrence or new-onset AF. During follow-up, fourteen patients (15%) reached the combined primary endpoint of stroke or new-onset AF. Multivariable cause specific regression analysis demonstrated that a lower LAEF was associated with the primary endpoint (Hazard Ratio [HR], 1.41 per 5% decrease [95% CI, 1.09-1.82]) as well as LA enlargement (HR: 1.98 per 5 ml/m2 increase [95% CI 1.11-3.52]). LA fibrosis did not show any associations with the combined endpoint (HR 1.01 [95% CI 0.95-1.07]), or any of its components.
conclusionIn patients with recent stroke, LAEF and LA enlargement, but not LA fibrosis, are associated with stroke recurrence or new-onset AF. Further studies are required to determine, whether LAEF as a component of ACM is a modifiable risk factor to reduce the risk of recurrent stroke and/or new-onset AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.